• 1
    Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007; 297: 813-819.
  • 2
    Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 12-19.
  • 3
    Seoud M, Tjalma WA, Ronsse V. Cervical adenocarcinoma: moving towards better prevention. Vaccine. 2011; 29: 9148-9158.
  • 4
    FUTURE I/II Study Group, Dillner J, Kjaer SK, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010; 341: c3493.
  • 5
    Kjaer SK, Sigurdsson K, Iversen OE. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila). 2009; 2: 868-878.
  • 6
    Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011; 365: 1576-1585.
  • 7
    Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J. 2007; 26: 201-209.
  • 8
    Block SL, Nolan T, Sattler C, et al; Protocol 016 Study Group. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006; 118: 2135-2145.
  • 9
    LeBaron CW, Massoudi M, Stevenson J, Lyons B. Vaccination coverage and physician distribution in the United States, 1997. Pediatrics. 2001; 107: E31.
  • 10
    Schluterman NH, Terplan M, Lydecker AD, Tracy JK. Human papillomavirus (HPV) vaccine uptake and completion at an urban hospital. Vaccine. 2011; 29: 3767-3772.
  • 11
    Chao C, Velicer C, Slezak JM, Jacobsen SJ. Correlates for completion of 3-dose regimen of HPV vaccine in female members of a managed care organization. Mayo Clin Proc. 2009; 84: 864-870.
  • 12
    Tan W, Viera AJ, Rowe-West B, Grimshaw A, Quinn B, Walter EB. The HPV vaccine: are dosing recommendations being followed? Vaccine. 2011; 29: 2548-2554.
  • 13
    Chandra A, Martinez GM, Mosher WD, Abma JC, Jones J. Fertility, family planning, and reproductive health of U.S. women: data from the 2002 National Survey of Family Growth. Vital Health Stat. 23. 2005;( 23): 1-160.
  • 14
    Jacobson VJ, Szilagyi P. Patient reminder and recall systems to improve immunization rates. Cochrane Database Syst Rev. 2005;( 3): CD003941.
  • 15
    Kharbanda EO, Stockwell MS, Fox HW, Andres R, Lara M, Rickert VI. Text message reminders to promote human papillomavirus vaccination. Vaccine. 2011; 29: 2537-2541.
  • 16
    Neubrand TP, Breitkopf CR, Rupp R, Breitkopf D, Rosenthal SL. Factors associated with completion of the human papillomavirus vaccine series. Clin Pediatr (Phila). 2009; 48: 966-969.
  • 17
    Castellsague X, Munoz N, Pitisuttithum P, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer. 2011; 105: 28-37.
  • 18
    Brisson M, van de Velde N, Franco EL, Drolet M, Boily MC. Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. J Infect Dis. 2011; 204: 372-376.
  • 19
    Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine. 2010; 28: 6858-6867.
  • 20
    Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13 through 17 years-United States, 2010. MMWR Morb Mortal Wkly Rep. 2011; 60: 1117-1123.